Press release
Metastatic Castration-Resistant Prostate Cancer Pipeline Analysis: 25+ Companies Advancing the Future of mCRPC Therapeutics | DelveInsight
Key Takeaways from the Metastatic Castration-Resistant Prostate Cancer Pipeline Report
• DelveInsight's mCRPC pipeline report depicts a robust pipeline landscape with 25+ active companies developing 30+ pipeline therapies for metastatic castration-resistant prostate cancer treatment.
• Key metastatic castration-resistant prostate cancer companies such as AstraZeneca, Cardiff Oncology, Janux Therapeutics, Olema Oncology, Eli Lilly and Company, K36 Therapeutics, and others are actively involved in developing innovative therapies for mCRPC.
• Promising metastatic castration-resistant prostate cancer pipeline therapies in various stages of development include Capivasertib, Onvansertib, JANX 007, PNT2002, OP-3136, and others.
Request a sample and discover the recent advances in metastatic castration-resistant prostate cancer treatment drugs.https://www.delveinsight.com/sample-request/metastatic-castration-resistant-prostate-cancer-pipeline-insight?utmsource=openpr&utm_medium=pressrelease&utm_campaign=kspr
What is Metastatic Castration-Resistant Prostate Cancer (mCRPC)?
Metastatic castration-resistant prostate cancer (mCRPC) is an advanced form of prostate cancer in which the disease continues to progress despite low testosterone levels achieved through androgen deprivation therapy. The disease spreads beyond the prostate gland to other parts of the body including bones, lymph nodes, liver, lungs, bladder, and in some cases, the brain.
Symptoms of mCRPC include trouble urinating, pain while passing urine, blood in urine, bone pain, fatigue, weakness, weight loss, and shortness of breath. Risk factors include advanced age, family history of prostate cancer, BRCA1/BRCA2 genetic mutations, elevated prostate-specific antigen (PSA) levels, and resistance to androgen deprivation therapy.
Diagnosis is primarily based on medical history, PSA testing, imaging procedures such as MRI and transrectal ultrasonography, and prostate biopsy. Treatment options include chemotherapy, immunotherapy, second-line hormone therapies, and radiopharmaceutical therapies.
Emerging Metastatic Castration-Resistant Prostate Cancer Drug Profiles
PNT2002: Eli Lilly and Company
PNT2002 is a radioconjugate composed of a human prostate-specific membrane antigen (PSMA)-targeting ligand conjugated to the beta-emitting radioisotope lutetium Lu 177. The therapy targets and binds to PSMA-expressing tumor cells and destroys them through targeted beta particle radiation delivery. The therapy is currently being evaluated in Phase III clinical development for metastatic castration-resistant prostate cancer.
In April 2023, the FDA granted Fast Track designation to 177Lu-PNT2002 for the treatment of patients with metastatic castration-resistant prostate cancer.
Onvansertib: Cardiff Oncology
Onvansertib is an oral polo-like kinase 1 (PLK1) inhibitor being developed for metastatic castration-resistant prostate cancer. The therapy is currently in Phase II clinical development and is being investigated for its ability to inhibit cancer cell proliferation and tumor progression.
Recent Developments in the Metastatic Castration-Resistant Prostate Cancer Pipeline Landscape
• In January 2026, ARTBIO commenced dosing of two cohorts in the US as part of its ARTISAN Phase I clinical trial of AB001 for the treatment of metastatic castration-resistant prostate cancer.
• In August 2025, the FDA granted Fast Track designation to HLD-0915 for the treatment of patients with metastatic castration-resistant prostate cancer.
• In December 2023, Eli Lilly and Company announced the successful completion of its acquisition of POINT Biopharma Global Inc., strengthening its radiopharmaceutical oncology pipeline.
• In November 2022, Lantheus Holdings, Inc. and POINT Biopharma Global Inc. announced strategic collaboration agreements for the development and commercialization of PNT2002 and PNT2003.
• In January 2024, Lava Therapeutics announced a clinical trial collaboration and supply agreement with Merck to evaluate LAVA-1207 in combination with Keytruda for prostate cancer treatment.
Scope of the Metastatic Castration-Resistant Prostate Cancer Pipeline Report
• Coverage: Global
• Therapeutic Assessment By Product Type: Mono, Combination, Mono/Combination
• Therapeutic Assessment By Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III
• Therapeutics Assessment By Route of Administration: Oral, Intravenous, Parenteral
• Therapeutics Assessment By Molecule Type: Small molecule, Recombinant fusion proteins, Radiopharmaceuticals
• Key Metastatic Castration-Resistant Prostate Cancer Companies: AstraZeneca, Cardiff Oncology, Janux Therapeutics, Olema Oncology, Eli Lilly and Company, K36 Therapeutics, and others
• Key Metastatic Castration-Resistant Prostate Cancer Pipeline Therapies: Capivasertib, Onvansertib, JANX 007, PNT2002, OP-3136, and others
Dive deep into rich insights for new drugs for metastatic castration-resistant prostate cancer treatment.
.https://www.delveinsight.com/sample-request/metastatic-castration-resistant-prostate-cancer-pipeline-insight?utmsource=openpr&utm_medium=pressrelease&utm_campaign=kspr
Table of Contents
1. Metastatic Castration-Resistant Prostate Cancer Pipeline Report Introduction
2. Metastatic Castration-Resistant Prostate Cancer Pipeline Report Executive Summary
3. Metastatic Castration-Resistant Prostate Cancer: Overview
4. Analytical Perspective In-depth Commercial Assessment
5. Metastatic Castration-Resistant Prostate Cancer Pipeline Therapeutics
6. Late Stage Products (Registration)
7. Late Stage Products (Phase III)
8. Mid Stage Products (Phase II)
9. Early Stage Products (Phase I)
10. Preclinical Stage Products
11. Metastatic Castration-Resistant Prostate Cancer Pipeline Therapeutics Assessment
12. Inactive Products in the Pipeline
13. Company-University Collaborations (Licensing/Partnering/Funding) Analysis
14. Key Companies
15. Key Products in the Pipeline
16. Unmet Needs
17. Market Drivers and Barriers
18. Future Perspectives and Conclusion
19. Analyst Views
20. Appendix
For further information on the metastatic castration-resistant prostate cancer pipeline therapeutics, reach out to DelveInsight.
.https://www.delveinsight.com/sample-request/metastatic-castration-resistant-prostate-cancer-pipeline-insight?utmsource=openpr&utm_medium=pressrelease&utm_campaign=kspr
Company Name: DelveInsight
Contact Person: Kirti Sharma
Email: info@delveinsight.com
Phone: +14699457679
Address: 304 S. Jones Blvd #2432
City: Albany
State: New York
About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance. Get hassle-free access to all the healthcare and pharma market research reports through its subscription-based platform PharmDelve.
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Metastatic Castration-Resistant Prostate Cancer Pipeline Analysis: 25+ Companies Advancing the Future of mCRPC Therapeutics | DelveInsight here
News-ID: 4538498 • Views: …
More Releases from DelveInsight Business Research LLP
Gout Pipeline Gains Momentum: 25+ Companies Lead the Charge in Pioneering New Tr …
DelveInsight's, "Gout Pipeline Insight 2026" report provides comprehensive insights about 25+ companies and 30+ pipeline drugs in Gout pipeline landscape. It covers the Gout pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Gout pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Download DelveInsight's comprehensive Gout Pipeline Report to explore emerging therapies…
The Mobile Clinics Market Size is estimated to grow at a CAGR of 5.99% by 2032, …
DelveInsight's Mobile Clinics Market Insights Report 2032 provides the current and forecast market analysis, individual leading Mobile Clinics Companies market shares, challenges, Mobile Clinics Market Drivers, barriers, trends, and key market Mobile Clinics companies in the market.
To read more about the latest highlights related to the Mobile Clinics Market, get a snapshot of the key highlights entailed in the Market Report @ https://www.delveinsight.com/sample-request/Mobile-Clinics-Market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr
Key Takeaways from the Mobile Clinics Market Report
•…
The Vein Illumination Devices Market Size is estimated to grow at a CAGR of 4.13 …
DelveInsight's Vein Illumination Devices Market Insights Report 2032 provides the current and forecast market analysis, individual leading Vein Illumination Devices Companies market shares, challenges, Vein Illumination Devices Market Drivers, barriers, trends, and key market Vein Illumination Devices companies in the market.
To read more about the latest highlights related to the Vein Illumination Devices Market, get a snapshot of the key highlights entailed in the Market Report @ https://www.delveinsight.com/sample-request/vein-illumination-devices-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr
Key Takeaways from…
The Bioanalytical Testing Services Market Size is estimated to grow at a CAGR of …
DelveInsight's Bioanalytical Testing Services Market Insights Report 2032 provides the current and forecast market analysis, individual leading Bioanalytical Testing Services Companies market shares, challenges, Bioanalytical Testing Services Market Drivers, barriers, trends, and key market Bioanalytical Testing Services companies in the market.
To read more about the latest highlights related to the Bioanalytical Testing Services Market, get a snapshot of the key highlights entailed in the Market Report @ https://www.delveinsight.com/sample-request/bioanalytical-testing-services-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr
Key Takeaways from…
More Releases for Metastatic
Metastatic Uveal Melanoma Pipeline Analysis: Emerging Targeted and Immunotherape …
DelveInsight's Metastatic Uveal Melanoma Pipeline Insight 2026 report provides comprehensive global coverage of available, marketed, and pipeline metastatic uveal melanoma therapies in various stages of clinical development. Major pharmaceutical and biotechnology companies are actively advancing innovative therapeutic strategies to address the high unmet need in metastatic uveal melanoma treatment.
Key takeaways from the Metastatic Uveal Melanoma Clinical Trial Landscape Report
• DelveInsight's metastatic uveal melanoma pipeline report depicts a growing therapeutic landscape with…
Key Trends Reshaping the Metastatic Bone Disease Market: Advancements in Targete …
Use code ONLINE30 to get 30% off on global market reports and stay ahead of tariff changes, macro trends, and global economic shifts.
Metastatic Bone Disease Market Size Growth Forecast: What to Expect by 2025?
The market size for metastatic bone disease has seen a quick expansion in the past few years. This market will increase from a value of $17.14 billion in 2024 to $18.88 billion in 2025, with a compound…
Emerging Trends Influencing The Growth Of The Metastatic Urothelial Carcinoma Ma …
We've updated all our reports with current data on tariff changes, trade developments, and supply chain shifts affecting key industries.
How Big Is the Metastatic Urothelial Carcinoma Market Size Expected to Be by 2034?
The market size for metastatic urothelial carcinoma has seen exponential growth recently. The market will expand from a worth of $1.18 billion in 2024 to $1.42 billion in 2025, with a compound annual growth rate (CAGR) of 20.2%.…
Key Influencer in the Metastatic Cancer Drugs Market 2025: Surging Prevalence Of …
How Are the key drivers contributing to the expansion of the metastatic cancer drugs market?
The escalation in the incidence of metastatic cancers will be a driving force for the expansion of the metastatic cancer drugs market. Metastatic cancer is a late-stage cancer that spreads across the body. As the number of metastatic cancer cases escalates, so does the creation of innovative drugs to treat various kinds of metastatic cancers. The…
Major Force in the Metastatic Bone Disease Market 2025: Impact Of Bone Cancer Pr …
How Will the Metastatic Bone Disease Market Grow, and What Is the Projected Market Size?
The market size for metastatic bone disease has seen considerable growth in recent years. There is an expected increase from $17.14 billion in 2024 to $18.88 billion in 2025, with a compound annual growth rate (CAGR) of 10.1%. The substantial growth during the historical period can be credited to factors like rising aging population, heightened cancer…
Combination Therapy Strategies for Metastatic Cancer
Metastatic cancer, where cancer cells spread from the primary tumor to distant organs, presents significant treatment challenges. Combination therapy strategies have emerged as a powerful approach to enhance treatment efficacy, overcome resistance, and improve patient outcomes in metastatic cancer.
Download Report:
https://www.kuickresearch.com/report-cancer-antibody-combinations-therapy-cancer-antibody-combination-monoclonal-antibodies-combination-drug-conjugate-antibodies-combination
One of the primary goals of combination therapy in metastatic cancer is to target both the primary tumor and metastatic sites. This comprehensive approach can improve overall disease control…
